Hypomagnesemia after cisplatin combination chemotherapy

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Cisplatin-based chemotherapy is a cornerstone in treating various cancers.
• Hypomagnesemia, a potential side effect of cisplatin, can lead to significant complications.
• Understanding the incidence and risk factors for hypomagnesemia is crucial for patient management.

Purpose of the Study:

• To investigate the incidence and severity of hypomagnesemia in patients receiving a specific five-drug combination chemotherapy regimen including low-dose cisplatin.
• To determine the relationship between hypomagnesemia and cumulative cisplatin dose, treatment frequency, and interval between cycles.

Main Methods:

• Prospective study of 66 patients undergoing a five-drug chemotherapy regimen with low-dose cisplatin.
• Monitoring of serum magnesium levels throughout the treatment course.
• Analysis of hypomagnesemia incidence based on cumulative cisplatin dose and treatment cycle intervals (4 weeks vs. 8 weeks).

Main Results:

• Hypomagnesemia was observed in 76% of 50 patients treated every four weeks.
• The incidence of hypomagnesemia significantly increased with cumulative cisplatin dose, from 41% after one cycle to 100% after six cycles.
• A lower incidence of hypomagnesemia was noted in patients with an eight-week interval between cycles compared to a four-week interval.

Conclusions:

• Hypomagnesemia is a frequent and dose-dependent complication of this cisplatin-containing chemotherapy regimen.
• Treatment frequency and cumulative cisplatin dose are key factors influencing hypomagnesemia incidence.
• Longer intervals between chemotherapy cycles may reduce the risk of hypomagnesemia, warranting further investigation into potential drug interactions.